Key Drivers
- High gross margins
- Positive free cashflow
- Large operating expenses
AIAI Summary
CareDx's transformation from a volume‑driven transplant‑testing company into a diagnostics-plus-data platform materially raises upside optionality and recurring‑revenue potential, but the investment hinges on two binary execution events—favorable final CMS LCD terms and clear early commercial traction for VANTx/next‑gen NGS (AlloHeme/AlloSeq)—so investors should prioritize monitoring the LCD decision and weekly/monthly commercial KPIs (bookings, ASPs, VANTx adoption, and RCM lift) over headline revenue guides. If LCD outcomes are supportive and initial platform metrics show repeatable adoption while OpEx growth moderates, valuation re‑rating is likely; conversely, adverse LCD terms or weak commercialization would keep multiples depressed.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Positive free cashflow
- •Large operating expenses
CareDx combines strong product-level profitability and ample liquidity with positive free cash flow, but persistent high operating expenses and accumulated deficits keep overall profitability and valuation contingent on sustained margin improvement.
Price Behavior
Key Price Behavior Insights:
- •Price below average
- •Lower highs/lows
- •Repeated support
Over the last month CDNA is in a short-term downtrend (price below the 21-day average) with resistance at $18.70–$19.30 and support around $16.40–$17.20 amid elevated mid‑teen percent volatility.
Mid‑teen percent range between period low and high, signaling elevated short-term volatility
Sentiment & News
Key News Insights:
- •Revenue +25%
- •COO → CFO
- •VANTx AI launch
CareDx posted strong Q4 revenue growth (+25%) but missed EPS estimates, announced a COO-to-CFO leadership consolidation, granted inducement RSUs, and launched the VANTx AI platform while attracting increased institutional interest.
Leadership consolidation and the new AI/data platform bolster strategic growth prospects, but the EPS miss may create near-term selling pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings